HCRTR1 Ile408Val

HCRTR1 Ile408Val — The Orexin Receptor Migraine Variant

The orexin system | Also called hypocretin. A pair of neuropeptides
(orexin-A and orexin-B) produced by a small cluster of neurons in the
lateral hypothalamus. Named from the Greek "orexis" (appetite), but
now known to regulate far more than hunger is one of the brain's
master regulators, orchestrating the balance between wakefulness and
sleep, appetite and satiety, arousal and calm. The HCRTR1 gene encodes
the orexin receptor 1 (OX1R) | A G-protein coupled receptor with
preferential affinity for orexin-A. Widely expressed in the locus
coeruleus, prefrontal cortex, hippocampus, and amygdala — brain
regions governing alertness, fear, and memory, the primary target
for orexin-A signaling. The rs2271933 variant causes an isoleucine-to-valine
substitution at position 408, altering the receptor's cytoplasmic tail
and potentially changing how it couples to downstream G-protein
signaling cascades.

The Mechanism

The Ile408Val substitution occurs in the
C-terminal intracellular domain | The portion of the receptor inside
the cell, responsible for interacting with G-proteins and other
signaling molecules that relay the orexin signal to cellular
machinery of HCRTR1, a region critical for G-protein coupling
and signal transduction. While the precise functional consequence
of this amino acid change has not been fully characterized in vitro,
the valine substitution may alter the receptor's interaction with
intracellular signaling partners, subtly shifting orexin-A signal
strength or duration. This is consistent with findings that the A
allele is associated with
altered hypocretin-1 concentrations | Kowalska M et al. The New
G29A and G1222A of HCRTR1, 5-HTTLPR of SLC6A4 Polymorphisms and
Hypocretin-1, Serotonin Concentrations in Migraine Patients. Front
Mol Neurosci, 2018 and
modified serotonin levels, suggesting downstream effects on
neurotransmitter systems implicated in both migraine and mood.

The Evidence

The strongest evidence links rs2271933 to migraine. A
case-control study of 384 migraineurs and 259 controls | Rainero I
et al. Evidence for an association between migraine and the hypocretin
receptor 1 gene. J Headache Pain, 2011
found the A allele carried an OR of 1.42 (95% CI 1.11-1.81) for
migraine risk, with the association specific to migraine without aura.
In women, the effect was more pronounced (OR 1.80, 95% CI 1.22-2.65,
p=0.003), while no significant association emerged in men.

The same research group found the A allele associated with
major mood disorders | Rainero I et al. Association between major
mood disorders and the hypocretin receptor 1 gene. J Affect Disord,
2011 at OR 1.60 (95% CI
1.22-2.10) in 229 patients versus 259 controls, with the association
confirmed in the unipolar depression subgroup.

A large
panic disorder meta-analysis | Gottschalk MG et al. Orexin in the
anxiety spectrum: association of a HCRTR1 polymorphism with panic
disorder/agoraphobia, CBT treatment response and fear-related
intermediate phenotypes. Transl Psychiatry, 2019
combined two independent cohorts (613 patients, 2,512 controls) and
found a striking association (allelic OR 1.51, p=4.2x10^-7),
particularly in women (recessive OR 2.59, p=9.8x10^-9). Risk allele
carriers also showed poorer response to cognitive behavioral therapy
and altered brain activation patterns — decreased inferior frontal
gyrus and increased locus coeruleus | The brain's primary
norepinephrine-producing nucleus, critical for arousal, attention,
and the fight-or-flight response activation during attention tasks.

In two
Estonian birth cohorts | Harro J et al. Orexin/hypocretin receptor
gene (HCRTR1) variation is associated with aggressive behaviour.
Neuropharmacology, 2019
totaling ~1,238 participants, A/A homozygotes reported higher
aggression scores, with the effect moderated by stressful life
events, particularly in women.

Practical Implications

The convergence of migraine, panic disorder, mood disorders, and
altered arousal in one receptor variant reflects the orexin system's
central role in regulating the brain's overall excitability state.
The A allele appears to shift the orexin signaling balance toward
heightened arousal reactivity — useful for vigilance, but at the
cost of increased vulnerability to conditions driven by neural
hyperexcitability.

For migraine specifically, the orexin connection opens a distinct
management angle. Orexin receptor antagonists (suvorexant,
lemborexant) are FDA-approved for insomnia and are being investigated
for migraine prevention. A/A carriers who experience both migraine
and sleep difficulties may be particularly suited for discussion of
these agents with their physician. The strong female predominance
in the associations suggests hormonal modulation of orexin signaling,
consistent with the known estrogen-orexin interaction.

Interactions

HCRTR1 rs2271933 likely interacts with the broader arousal and
neuropeptide network. The neuropeptide S receptor gene NPSR1
(rs324981) is a functionally analogous variant — both encode
arousal-promoting receptor changes associated with panic disorder,
and carriers of risk alleles at both loci may experience compounded
arousal dysregulation. BDNF Val66Met (rs6265) could modulate the
stress resilience component, as both BDNF and orexin pathways
converge on prefrontal-limbic circuits. However, specific gene-gene
interaction studies for HCRTR1 rs2271933 combined with these variants
have not yet been published, so these interactions remain theoretical.